<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d408">
    <sentence id="DDI-DrugBank.d408.s0" text="No formal drug interaction studies have been performed with ZEVALIN.">
        <entity id="DDI-DrugBank.d408.s0.e0" charOffset="60-66"
            type="brand" text="ZEVALIN"/>
    </sentence>
    <sentence id="DDI-DrugBank.d408.s1" text="Due to the frequent occurrence of severe and prolonged thrombocytopenia, the potential benefits of medications which interfere with platelet function and/or anticoagulation should be weighed against the potential increased risks of bleeding and hemorrhage."/>
    <sentence id="DDI-DrugBank.d408.s2" text="Patients receiving medications that interfere with platelet function or coagulation should have more frequent laboratory monitoring for thrombocytopenia."/>
    <sentence id="DDI-DrugBank.d408.s3" text="In addition, the transfusion practices for such patients may need to be modified given the increased risk of bleeding."/>
    <sentence id="DDI-DrugBank.d408.s4" text="Patients in clinical studies were prohibited from receiving growth factor treatment for 2 weeks prior to the ZEVALIN therapeutic regimen as well as for 2 weeks following completion of the regimen.">
        <entity id="DDI-DrugBank.d408.s4.e0" charOffset="109-115"
            type="brand" text="ZEVALIN"/>
    </sentence>
</document>
